IP
VRTX icon

Intellectus Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Intellectus Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,660
Closed -$1.03M – 271
2022
Q2 		$1.03M Sell
3,660
-87
-2% -$23.3K 0.35% 79
2022
Q1 		$978K Sell
3,747
-174
-4% -$41.3K 0.29% 88
2021
Q4 		$861K Buy
3,921
+343
+10% +$66.7K 0.22% 120
2021
Q3 		$649K Buy
3,578
+397
+12% +$77.5K 0.16% 162
2021
Q2 		$641K Buy
+3,181
New +$665K 0.14% 174

Other funds holding VRTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Intellectus Partners's VRTX Position: Q3 2022 in Review

Intellectus Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2022, closing a stake of 3,660 shares — an estimated $1.03M sold.

Intellectus Partners first reported a position in VRTX in Q2 2021 and held it in 5 quarters. The position peaked at $1.03M in Q2 2022. 1,127 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

  • Intellectus Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Intellectus Partners sold 3,660 Vertex Pharmaceuticals shares in Q3 2022, an estimated $1.03M.
  • Intellectus Partners first reported a position in Vertex Pharmaceuticals in Q2 2021 and held it in 5 quarters.
  • Intellectus Partners's Vertex Pharmaceuticals position peaked at $1.03M in Q2 2022.
  • 1,127 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Intellectus Partners's 13F filing for Q3 2022, filed 14 Nov 2022.